• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一个灵活的多结构域结构驱动尿激酶型纤溶酶原激活物受体(uPAR)的功能。

A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR).

机构信息

Finsen Laboratory, Rigshospitalet and Biotech Research and Innovation Centre (BRIC), Copenhagen Biocenter, Ole Maaløes Vej 5, DK-2200 Copenhagen N, Denmark.

出版信息

J Biol Chem. 2012 Oct 5;287(41):34304-15. doi: 10.1074/jbc.M112.398404. Epub 2012 Aug 15.

DOI:10.1074/jbc.M112.398404
PMID:22896701
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3464537/
Abstract

The urokinase-type plasminogen activator receptor (uPAR) provides a rendezvous between proteolytic degradation of the extracellular matrix and integrin-mediated adhesion to vitronectin. These processes are, however, tightly linked because the high affinity binding of urokinase regulates the binding of uPAR to matrix-embedded vitronectin. Although crystal structures exist to define the corresponding static bi- and trimolecular receptor complexes, it is evident that the dynamic property of uPAR plays a decisive role in its function. In the present study, we combine small angle x-ray scattering, hydrogen-deuterium exchange, and surface plasmon resonance to develop a structural model describing the allosteric regulation of uPAR. We show that the flexibility of its N-terminal domain provides the key for understanding this allosteric mechanism. Importantly, our model has direct implications for understanding uPAR-assisted cell adhesion and migration as well as for translational research, including targeted intervention therapy and non-invasive tumor imaging in vivo.

摘要

尿激酶型纤溶酶原激活物受体 (uPAR) 为细胞外基质的蛋白水解降解和整合素介导的对玻连蛋白的黏附作用提供了一个连接点。然而,这两个过程紧密相连,因为尿激酶的高亲和力结合调节了 uPAR 与基质结合的玻连蛋白的结合。尽管已经存在用于定义相应的静态双分子和三分子受体复合物的晶体结构,但显然 uPAR 的动态特性在其功能中起着决定性的作用。在本研究中,我们结合小角度 X 射线散射、氘氢交换和表面等离子体共振,开发了一个描述 uPAR 变构调节的结构模型。我们表明,其 N 端结构域的灵活性为理解这种变构机制提供了关键。重要的是,我们的模型对理解 uPAR 辅助的细胞黏附和迁移以及转化研究具有直接意义,包括靶向干预治疗和体内非侵入性肿瘤成像。

相似文献

1
A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR).一个灵活的多结构域结构驱动尿激酶型纤溶酶原激活物受体(uPAR)的功能。
J Biol Chem. 2012 Oct 5;287(41):34304-15. doi: 10.1074/jbc.M112.398404. Epub 2012 Aug 15.
2
Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation.稳定含有 SMB 结合位点的柔性结构域铰链区可将 uPAR 驱动至其关闭构象。
J Mol Biol. 2015 Mar 27;427(6 Pt B):1389-1403. doi: 10.1016/j.jmb.2015.01.022. Epub 2015 Feb 7.
3
Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.尿激酶受体上玻连蛋白结合位点的定位:由结构域I和侧翼结构域间连接区的残基组成的连贯受体界面的参与。
J Biol Chem. 2007 May 4;282(18):13561-72. doi: 10.1074/jbc.M610184200. Epub 2007 Mar 13.
4
Discovery of new small molecules targeting the vitronectin-binding site of the urokinase receptor that block cancer cell invasion.发现新的小分子,靶向尿激酶受体的 vitronectin 结合位点,阻断癌细胞侵袭。
Mol Cancer Ther. 2013 Aug;12(8):1402-16. doi: 10.1158/1535-7163.MCT-12-1249. Epub 2013 May 22.
5
A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.一类新型的正向变构uPAR·uPA小分子拮抗剂是uPAR·玻连蛋白相互作用的别构抑制剂。
ACS Chem Biol. 2015 Jun 19;10(6):1521-34. doi: 10.1021/cb500832q. Epub 2015 Mar 31.
6
Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor.引入尿激酶受体中非天然的结构域间二硫键模拟其在片状伪足形成中的调节作用。
J Biol Chem. 2011 Dec 16;286(50):43515-26. doi: 10.1074/jbc.M111.300020. Epub 2011 Oct 24.
7
Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor.甘露糖6-磷酸/胰岛素样生长因子2受体通过控制αVβ3整合素的表达和尿激酶型纤溶酶原激活剂受体的蛋白水解加工来限制细胞侵袭。
Mol Biol Cell. 2009 Feb;20(3):745-56. doi: 10.1091/mbc.e08-06-0569. Epub 2008 Nov 26.
8
Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.玻连蛋白通过捕获可溶性尿激酶受体-尿激酶复合物,将蛋白水解活性集中于细胞表面和细胞外基质。
Blood. 1998 Apr 1;91(7):2305-12.
9
Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction.尿激酶受体功能的构象调节:受体占据和表位映射单克隆抗体对片状伪足诱导的影响。
J Biol Chem. 2011 Sep 23;286(38):33544-56. doi: 10.1074/jbc.M111.220087. Epub 2011 Jul 28.
10
Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes.尿激酶受体(uPAR)的合理靶向:拮抗剂和非侵入性成像探针的开发。
Curr Drug Targets. 2011 Nov;12(12):1711-28. doi: 10.2174/138945011797635812.

引用本文的文献

1
Targeted imaging of uPAR expression in vivo with cyclic AE105 variants.用环 AE105 变体在体内靶向成像 uPAR 表达。
Sci Rep. 2023 Oct 11;13(1):17248. doi: 10.1038/s41598-023-43934-w.
2
Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View.尿激酶受体信号传导对细胞功能的调节:一种机制性观点
Front Cell Dev Biol. 2022 Apr 8;10:818616. doi: 10.3389/fcell.2022.818616. eCollection 2022.
3
Crystal structure and cellular functions of uPAR dimer.uPAR 二聚体的晶体结构和细胞功能。
Nat Commun. 2022 Mar 29;13(1):1665. doi: 10.1038/s41467-022-29344-y.
4
Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer.尿激酶型纤溶酶原激活物受体(uPAR)作为癌症的治疗靶点。
J Transl Med. 2022 Mar 18;20(1):135. doi: 10.1186/s12967-022-03329-3.
5
Polymeric biocompatible iron oxide nanoparticles labeled with peptides for imaging in ovarian cancer.多肽标记的聚合物生物相容性氧化铁纳米颗粒用于卵巢癌成像。
Biosci Rep. 2022 Feb 25;42(2). doi: 10.1042/BSR20212622.
6
The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities.尿激酶受体(uPAR)作为靶向癌症治疗中的“特洛伊木马”:挑战与机遇
Cancers (Basel). 2021 Oct 27;13(21):5376. doi: 10.3390/cancers13215376.
7
suPAR, a Circulating Kidney Disease Factor.可溶性尿激酶型纤溶酶原激活物受体,一种循环性肾脏疾病因子。
Front Med (Lausanne). 2021 Oct 6;8:745838. doi: 10.3389/fmed.2021.745838. eCollection 2021.
8
Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention.以非侵入性成像和治疗干预为目的,针对人类疾病中的尿激酶型纤溶酶原激活物受体(uPAR)
Front Cell Dev Biol. 2021 Aug 20;9:732015. doi: 10.3389/fcell.2021.732015. eCollection 2021.
9
The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications.尿激酶型纤溶酶原激活物受体:癌细胞生物学中的多功能受体。治疗意义。
Int J Mol Sci. 2021 Apr 16;22(8):4111. doi: 10.3390/ijms22084111.
10
Design and Synthesis of Fragment Derivatives with a Unique Inhibition Mechanism of the uPAR·uPA Interaction.具有独特抑制机制的尿激酶型纤溶酶原激活物受体(uPAR)·尿激酶型纤溶酶原激活物(uPA)相互作用的片段衍生物的设计与合成
ACS Med Chem Lett. 2020 Dec 10;12(1):60-66. doi: 10.1021/acsmedchemlett.0c00422. eCollection 2021 Jan 14.

本文引用的文献

1
, a program for rapid shape determination in small-angle scattering.用于小角散射中快速形状测定的一个程序。
J Appl Crystallogr. 2009 Apr 1;42(Pt 2):342-346. doi: 10.1107/S0021889809000338. Epub 2009 Jan 24.
2
New developments in the program package for small-angle scattering data analysis.小角散射数据分析程序包的新进展。
J Appl Crystallogr. 2012 Mar 15;45(Pt 2):342-350. doi: 10.1107/S0021889812007662. eCollection 2012 Apr 1.
3
Crystal structure of the urokinase receptor in a ligand-free form.尿激酶型纤溶酶原激活物受体在无配体形式下的晶体结构。
J Mol Biol. 2012 Mar 9;416(5):629-41. doi: 10.1016/j.jmb.2011.12.058. Epub 2012 Jan 21.
4
Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion.用 64Cu-DOTA-AE105 进行人体尿激酶型纤溶酶原激活物受体的定量 PET:对可视化癌症侵袭的影响。
J Nucl Med. 2012 Jan;53(1):138-45. doi: 10.2967/jnumed.110.083386.
5
Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor.引入尿激酶受体中非天然的结构域间二硫键模拟其在片状伪足形成中的调节作用。
J Biol Chem. 2011 Dec 16;286(50):43515-26. doi: 10.1074/jbc.M111.300020. Epub 2011 Oct 24.
6
Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.尿激酶型纤溶酶原激活物受体与表皮生长因子受体变体 III 之间的串扰支持脑胶质母细胞瘤细胞的存活和生长。
Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15984-9. doi: 10.1073/pnas.1113416108. Epub 2011 Sep 6.
7
Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion.靶向多种构象可导致 uPAR·uPA 蛋白-蛋白相互作用的小分子抑制剂,从而阻断癌细胞侵袭。
ACS Chem Biol. 2011 Nov 18;6(11):1232-43. doi: 10.1021/cb200180m. Epub 2011 Sep 29.
8
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.循环尿激酶受体是局灶节段性肾小球硬化的病因。
Nat Med. 2011 Jul 31;17(8):952-60. doi: 10.1038/nm.2411.
9
Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction.尿激酶受体功能的构象调节:受体占据和表位映射单克隆抗体对片状伪足诱导的影响。
J Biol Chem. 2011 Sep 23;286(38):33544-56. doi: 10.1074/jbc.M111.220087. Epub 2011 Jul 28.
10
Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic.针对尿激酶型纤溶酶原激活物受体 (uPAR) 的新型治疗药物的开发及其向临床的转化。
Curr Pharm Des. 2011;17(19):1970-8. doi: 10.2174/138161211796718152.